CN
News & Events

News & Events

Chipscreen Highlights: Stay Updated on Recent Hot Topics

Select year

2026 2025 2024 2023 2022 Earlier
shown/page
5
5 10 15 20

2025.05.15

Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025
Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

Full text

2025.04.18

CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation
CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

Full text

2025.03.11

AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development
AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development

Full text

2024.11.18

Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price
Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price

Full text

2024.10.17

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

Full text
Media contact

Media contact

  • Media contact

    （+86）0755-36993500

  • Media contact

    pr@chipscreen.com